Cargando…

A Review of the Advancements in Targeted Therapies for Breast Cancer

Breast cancer, the second-most common and lethal disease in women, poses a severe danger to global health. Breast cancer rates continue to climb despite advances in medical technology. Predictions indicate that by 2040, there will be more than three million new cases yearly. Targeted medicines have...

Descripción completa

Detalles Bibliográficos
Autores principales: Jallah, John Kessellie, Dweh, Tuward J, Anjankar, Ashish, Palma, Ogiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679843/
https://www.ncbi.nlm.nih.gov/pubmed/38022130
http://dx.doi.org/10.7759/cureus.47847
_version_ 1785142258589237248
author Jallah, John Kessellie
Dweh, Tuward J
Anjankar, Ashish
Palma, Ogiza
author_facet Jallah, John Kessellie
Dweh, Tuward J
Anjankar, Ashish
Palma, Ogiza
author_sort Jallah, John Kessellie
collection PubMed
description Breast cancer, the second-most common and lethal disease in women, poses a severe danger to global health. Breast cancer rates continue to climb despite advances in medical technology. Predictions indicate that by 2040, there will be more than three million new cases yearly. Targeted medicines have experienced a profound transformation in treating breast cancer, allowing for individualized strategies that lessen side effects and improve patient outcomes. This thorough analysis gives a rigorous investigation of current developments in breast cancer-targeted treatments. It carefully examines several subtypes, including hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC), recognizing the illness' fundamental variety. It offers specialized treatment plans catered to each subtype's particular traits. The review also examines how precise genetic abnormalities like BRCA1/2 and PIK3CA mutations and molecular profiling facilitate therapy selection. Monoclonal antibodies and small molecule inhibitors are some of the targeted medicines examined in the study. It explains how each of these treatments works and supports its findings with data from clinical trials. It also considers potential new medications and addresses persistent problems, such as resistance mechanisms, chances for combining therapies, and cutting-edge patient classification techniques. This study seeks to give healthcare professionals, researchers, and patients a thorough overview of the recent advancements in breast cancer-targeted therapy by drawing on the opinions of top authorities in the area. The coordinated effort aims to create customized, efficient therapies, eventually bolstering the battle against this powerful illness.
format Online
Article
Text
id pubmed-10679843
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-106798432023-10-28 A Review of the Advancements in Targeted Therapies for Breast Cancer Jallah, John Kessellie Dweh, Tuward J Anjankar, Ashish Palma, Ogiza Cureus Epidemiology/Public Health Breast cancer, the second-most common and lethal disease in women, poses a severe danger to global health. Breast cancer rates continue to climb despite advances in medical technology. Predictions indicate that by 2040, there will be more than three million new cases yearly. Targeted medicines have experienced a profound transformation in treating breast cancer, allowing for individualized strategies that lessen side effects and improve patient outcomes. This thorough analysis gives a rigorous investigation of current developments in breast cancer-targeted treatments. It carefully examines several subtypes, including hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC), recognizing the illness' fundamental variety. It offers specialized treatment plans catered to each subtype's particular traits. The review also examines how precise genetic abnormalities like BRCA1/2 and PIK3CA mutations and molecular profiling facilitate therapy selection. Monoclonal antibodies and small molecule inhibitors are some of the targeted medicines examined in the study. It explains how each of these treatments works and supports its findings with data from clinical trials. It also considers potential new medications and addresses persistent problems, such as resistance mechanisms, chances for combining therapies, and cutting-edge patient classification techniques. This study seeks to give healthcare professionals, researchers, and patients a thorough overview of the recent advancements in breast cancer-targeted therapy by drawing on the opinions of top authorities in the area. The coordinated effort aims to create customized, efficient therapies, eventually bolstering the battle against this powerful illness. Cureus 2023-10-28 /pmc/articles/PMC10679843/ /pubmed/38022130 http://dx.doi.org/10.7759/cureus.47847 Text en Copyright © 2023, Jallah et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Epidemiology/Public Health
Jallah, John Kessellie
Dweh, Tuward J
Anjankar, Ashish
Palma, Ogiza
A Review of the Advancements in Targeted Therapies for Breast Cancer
title A Review of the Advancements in Targeted Therapies for Breast Cancer
title_full A Review of the Advancements in Targeted Therapies for Breast Cancer
title_fullStr A Review of the Advancements in Targeted Therapies for Breast Cancer
title_full_unstemmed A Review of the Advancements in Targeted Therapies for Breast Cancer
title_short A Review of the Advancements in Targeted Therapies for Breast Cancer
title_sort review of the advancements in targeted therapies for breast cancer
topic Epidemiology/Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679843/
https://www.ncbi.nlm.nih.gov/pubmed/38022130
http://dx.doi.org/10.7759/cureus.47847
work_keys_str_mv AT jallahjohnkessellie areviewoftheadvancementsintargetedtherapiesforbreastcancer
AT dwehtuwardj areviewoftheadvancementsintargetedtherapiesforbreastcancer
AT anjankarashish areviewoftheadvancementsintargetedtherapiesforbreastcancer
AT palmaogiza areviewoftheadvancementsintargetedtherapiesforbreastcancer
AT jallahjohnkessellie reviewoftheadvancementsintargetedtherapiesforbreastcancer
AT dwehtuwardj reviewoftheadvancementsintargetedtherapiesforbreastcancer
AT anjankarashish reviewoftheadvancementsintargetedtherapiesforbreastcancer
AT palmaogiza reviewoftheadvancementsintargetedtherapiesforbreastcancer